Assessment of maximum tolerated dose of a new herbal drug, Semelil (ANGIPARS™) in patients with diabetic foot ulcer: A Phase I clinical trial

Authors
Category Primary study
JournalDaru
Year 2008
This article has no abstract
Epistemonikos ID: 1a913703c49c082e11524850392cab64dcb76f5d
First added on: Feb 04, 2025